Pioneering longevity researcher joins SIRTLab to accelerate aging interventions
Longevity Technology - 09-May-2023Nir Barzilai brings his expertise to boost the company's mission to extend healthspan by targeting age-related diseases
Join the club for FREE to access the whole archive and other member benefits.
Drugs developer that increase SIRT6 to block the progression of diabetes and obesity
SirTLab Corporation's goal is to cure age-related diseases and extend healthy lifespan based on its breakthrough treatment methods that activate the gene SIRT6 on the cellular level. Its scientific team showed for the first and only time in the world that over-expressing the gene SIRT6 in body cells extends the lives of mice by 30%.
The Need to Activate SIRT6
The gene SIRT6 is a protein deacetylase and a member of the Sirtuins family.
Research over the last 15 years has provided evidence that when SIRT6 is activated, it has a profound effect on preventing and curing age-related diseases, e.g. overweight/obesity, diabetes, fatty liver, dyslipidemia (high level of cholesterol and triglycerides), cancer and other age-related diseases. However, activating SIRT6 is an extremely challenging task since it requires methods that work on the cellular level, an area where SirTLab Corporation has recently achieved a major breakthrough.
Visit website: https://www.sirtlabcorp.com/
Details last updated 11-May-2023
Nir Barzilai brings his expertise to boost the company's mission to extend healthspan by targeting age-related diseases